Compare Bristol-Myers Squibb Co (BMY) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.09. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| BMY | GPTY | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $50.52 |
52-Week Low | $42.60 | $34.73 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
GPTY trades at $43.50, down 2.2% today, with technical indicators showing mixed signals amid neutral overall momentum. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.30-$0.38. Support levels cluster around $43-44 while resistance sits at $45-46. Recent coverage highlights GPTY's focus on AI and tech exposure through option premium strategies, though some analysts question sustainability of current performance levels.
The outlook remains balanced with income generation from weekly dividends offset by technical weakness. Key risks include concentration in tech sector volatility and dependency on option strategy performance. Analyst sentiment appears divided between income-focused appeal and concerns about NAV erosion potential in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
